Sep. 9 at 4:22 PM
$RAPP Below drugs are already in market, doing well. Additionally, many other drugs are in late stage of development. Barely any room for RAP-219, if gets approved.
RAP-219's developer, Rapport Therapeutics, views the following marketed anti-seizure medications (ASMs) as competitors:
XCOPRI (cenobamate): A medication for focal seizures, which was approved by the FDA in 2019.
FYCOMPA (perampanel): This drug is a non-competitive AMPA receptor antagonist that works throughout the central nervous system
Keppra (levetiracetam): An anti-seizure medication that works by binding to a protein called SV2A, which is involved in the release of neurotransmitters.
Lamotrigine: This drug works by stabilizing voltage-gated sodium channels, preventing the high-frequency firing of neurons during a seizure.
Tegretol (carbamazepine): Another sodium channel blocker used to treat focal and generalized seizures.
Ezogabine (Potiga):potassium channel opener, acting on Kv7.2 and Kv7.3
